Jonathan Knutzen Sells 444 Shares of Palomar (NASDAQ:PLMR) Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) insider Jonathan Knutzen sold 444 shares of the firm’s stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $122.04, for a total value of $54,185.76. Following the sale, the insider directly owned 26,648 shares of the company’s stock, valued at $3,252,121.92. This trade represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Knutzen also recently made the following trade(s):

• On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The stock was sold at an average price of $122.04, for a total value of $54,185.76.
• On Saturday, January 31st, Jonathan Knutzen sold 290 shares of Palomar stock. The shares were sold at an average price of $121.74, for a total transaction of $35,304.60.
• On Wednesday, January 28th, Jonathan Knutzen sold 1,535 shares of Palomar stock. The stock was sold at an average price of $119.88, for a total transaction of $184,015.80.
• On Tuesday, November 18th, Jonathan Knutzen sold 281 shares of Palomar stock. The stock was sold at an average price of $128.84, for a total transaction of $36,204.04.

Palomar Price Performance

Shares of PLMR stock traded up $0.63 on Monday, hitting $124.22. The company’s stock had a trading volume of 240,836 shares, compared to its average volume of 180,129. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of 19.38 and a beta of 0.44. Palomar Holdings, Inc. has a fifty-two week low of $104.47 and a fifty-two week high of $175.85. The firm’s fifty day moving average price is $127.67 and its 200-day moving average price is $123.57.

Palomar (NASDAQ:PLMR) last announced its quarterly earnings results on Thursday, November 6th. The company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.45. The company had revenue of $244.66 million during the quarter, compared to analysts’ expectations of $207.98 million. Palomar had a return on equity of 21.93% and a net margin of 22.59%.During the same quarter in the previous year, the firm earned $1.23 earnings per share. Analysts predict that Palomar Holdings, Inc. will post 5.99 EPS for the current fiscal year.

More Palomar News

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Palomar closed the acquisition of The Gray Casualty & Surety Company, expanding its surety capabilities and product mix — a strategic tuck‑in that can add premium, diversify risk exposure and support growth in specialty lines. BCP Completes Sale of The Gray Casualty & Surety Company
• Neutral Sentiment: Palomar will report Q4 and full‑year 2025 results after the close on Feb 11, 2026, with a conference call Feb 12 — an event that typically drives short‑term volume and volatility as investors update estimates and listen for management commentary on reserve development, underwriting margin, and growth. Earnings Release & Conference Call
• Negative Sentiment: Multiple insiders (including the CEO, President, CFO and other senior executives) sold shares on Jan. 29 and Jan. 31, reducing positions by low-single-digit percentages in many cases. Heavy insider selling can signal liquidity taking or tax/comp planning, but it may concern some investors about insider confidence or timing ahead of earnings. Representative coverage of recent insider sales is here. CEO Sells Stock (Example)

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PLMR shares. Weiss Ratings raised shares of Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, January 14th. Keefe, Bruyette & Woods upped their price target on shares of Palomar from $170.00 to $171.00 and gave the company an “outperform” rating in a report on Tuesday, January 6th. Wall Street Zen raised Palomar from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, JPMorgan Chase & Co. boosted their price objective on Palomar from $145.00 to $155.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $159.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PLMR. Salomon & Ludwin LLC acquired a new stake in Palomar during the third quarter worth about $25,000. Richardson Financial Services Inc. lifted its position in shares of Palomar by 210.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock worth $25,000 after acquiring an additional 147 shares during the period. Allworth Financial LP lifted its position in shares of Palomar by 1,970.0% in the 2nd quarter. Allworth Financial LP now owns 207 shares of the company’s stock worth $32,000 after acquiring an additional 197 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Palomar during the 4th quarter worth approximately $32,000. Finally, Clearstead Advisors LLC increased its position in shares of Palomar by 31.0% during the third quarter. Clearstead Advisors LLC now owns 397 shares of the company’s stock valued at $46,000 after purchasing an additional 94 shares during the period. Institutional investors and hedge funds own 90.25% of the company’s stock.

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.